Orthofix Medical Inc. (NASDAQ:OFIX), a global medical technology company renowned for its innovative orthopedic solutions, recently unveiled its third-quarter 2025 financial results. The company reported an earnings per share (EPS) of -$0.57, falling short of the anticipated EPS of $0.12. Despite this setback, Orthofix's revenue reached approximately $205.6 million, exceeding the forecasted $200 million. Orthofix Medical Inc. (NASDAQ:OFIX) reported a Q3 2025 EPS of -$0.57, missing the estimated EPS of $0.12 ...

PresentationHello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Orthofix Third Quarter 2025 Earnings Conference Call. [Operator Instructions]Julie DeweyChief Investor Relations & Communications Officer Thank you, operator, and good morning, everyone. Welcome to Orthofix' Third Quarter 2025 Earnings Call. We appreciate you joining us. I'm Julie Dewey, Orthofix' Chief IR and Communications Officer. Joining ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Orthofix Medical (NasdaqGS:OFIX) Q3 2025 Earnings Call November 04, 2025 08:30 AM ET Speaker1Thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Orthofix Third Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star then ...

Orthofix (OFIX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +66.67%. A quarter ago, it was expected that this medical device maker would post earnings of $0.04 per share when it actually produced earnings of $0.13, delivering a surprise of +225%.Over the last four quarters, the com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisd ...

Pro Forma Financial Results Results excluding the impact of discontinuation of M6 product lines Net Sales by Major Product Category by Reporting Segment | | | | | Three Months Ended September | 30, | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | Constant | | | | | | | | Currency | | (Unaudited, U.S. Dollars, in millions) | | 2025 | | 2024 | Change | Change | | Bone Growth Therapies | $ | 61.2 | $ | 57.9 | 5.7% | 5.7% | | Spinal Implants, Biologics and Enabling Technologies* | | 108.6 | | 102.9 ...

Exhibit 99.1 News Release Orthofix Reports Third Quarter 2025 Financial Results LEWISVILLE, Texas — November 4, 2025 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's de ...

Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or Orthofix (OFIX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong ...

基金业绩表现 - RAM Smid Composite第二季度2025年增长6.11% 但略低于基准罗素2500价值总回报指数的7.29%涨幅 [1] - 年初至今该投资组合回报为-1.29% 而基准回报为1.03% [1] - 公司认为季度表现符合预期 并对2025年下半年中小盘价值板块保持信心 [1] Orthofix Medical公司概况 - Orthofix Medical Inc为医疗技术公司 业务涵盖全球脊柱和全球骨科两大板块 [2] - 公司一个月回报率为2.76% 但过去52周股价下跌9.8% [2] - 截至2025年9月12日 股价收于14.91美元 市值5.8886亿美元 [2] 投资持仓变动 - Rewey资产管理在2025年第二季度增持Orthofix Medical头寸 [3] - 增持决策基于股价较2月高点下跌45.6% 较2024年底下跌36.1% [3] - 公司认为当前估值具有吸引力 并获得CEO和大股东内部买入的支持 [3] 机构持仓情况 - 第二季度末共有25只对冲基金持有Orthofix Medical 较上季度的28只有所减少 [4] - 该股未入选对冲基金最受欢迎的30只股票名单 [4]